• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL TRIFECTA¿ GT VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL TRIFECTA¿ GT VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Catalog Number UNK TRIFECTA¿ GT VALVE
Device Problem Patient-Device Incompatibility (2682)
Patient Problems Valvular Stenosis (2697); Aortic Valve Insufficiency/ Regurgitation (4450)
Event Type  Injury  
Manufacturer Narrative
As reported in a research article, 994 patients underwent aortic valve replacement between october 2011 and october 2020.Events of aortic stenosis and aortic regurgitation were reported; the trifecta valve had a 1.4% all-cause reintervention rate at 10 years, with insignificant impact on survival.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review, and no device or additional patient information was received for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.
 
Event Description
The article "analysis of incidence and reasons for re-intervention after aortic valve replacement using the trifecta aortic bioprosthesis" was reviewed.This research article is a prospective multicentre experience to evaluate the perioperative patient and operative characteristics, and re-intervention rates and survival of patients undergoing surgical implantation of the trifecta and trifecta gt aortic bioprostheses in our center over a 10-year period.The trifecta and trifecta gt aortic bioprosthesis were involved in this study.The conclusion of this study was the trifecta valve had a 1.4% all-cause re-intervention rate at 10 years, with insignificant impact on survival.The primary author is [amir fard, md, university of glasgow, glasgow, uk, the corresponding author is [nawwar al-attar, professor, golden jubilee national hospital, agamemnon street, clydebank, g81 4dy, uk, nawwar.Alattar@gjnh.Scot.Nhs.Uk].
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRIFECTA¿ GT VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL #3014918977
edificio #44 calle 0, ave. 2
el coyol alajuela 1897- 4050
CS   1897-4050
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key14344736
MDR Text Key291275905
Report Number2135147-2022-00260
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeUK
PMA/PMN Number
P100029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature
Reporter Occupation Physician
Type of Report Initial
Report Date 05/10/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/10/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK TRIFECTA¿ GT VALVE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received04/12/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age73 YR
Patient SexMale
-
-